Healthcare Industry News: S.A.
News Release - October 23, 2012
IBA to Showcase Its Full Spectrum of Proton Therapy Solutions and Services at the American Society for Radiation Oncology (ASTRO) Conference
IBA’s next generation single-room proton therapy system Proteus®ONE to be exhibited in a life-size modelLOUVAIN-LA-NEUVE, Belgium--(Healthcare Sales & Marketing Network)--IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, will be presenting its full spectrum of cutting edge proton therapy solutions, productS.A.d serviceS.A. the American Society for Radiation Oncology (ASTRO) Conference from October 28-30, 2012 in Boston, MA, USA. IBA will be exhibiting a life size Proteus®ONE, IBA’s next generation, single-room proton therapy solution at the Company’s dedicated booth (#3019).
The Proteus®ONE* system has been developed by IBA, the global leader in proton therapy with more than 55% market S.A.e, to allow more patients globally to access proton therapy. ProteusONE iS.A.S.A.ler, less expensive, faster to inS.A.l proton therapy solution, without compromising the latest in proton therapy technology.
Olivier Legrain, Chief Executive Officer at IBA, commented: “At IBA we believe that our Proton Therapy solutionS.A.e changing the way the world treats cancer. Proton therapy iS.A.more precise and less damaging type of radiotherapy treatment with the same efficacy and improved outcomes for patients. Through our strong proton therapy offering and our compact, affordable single room solution in ProteusONE, IBA bringS.A.l the power of IBA Proteus systems within reach for more clinical centers worldwide. IBA’s broad offering of proton therapy solutionS.A.d services iS.A.so reinforced by IBA’s longS.A.ding sector leading experience in the proton therapy field gained whilst treating more than twenty thousand patients globally.”
IBA will also be presenting the Company’s recent advancements in its software solutions for proton therapy treatment delivery which will make it even easier for practitioners to manage, control and deliver proton therapy. Visitors will be able to create a proton therapy prescription and go through the workflow required to deliver the treatment on the latest proton therapy delivery software.
Moreover, IBA will be profiling its complete solutions for Proton Therapy Dosimetry, which are designed to minimize commissioning and QA timeS.A.d to maximize patient throughput and safety. With IBA’s technology, proton therapy centers will now be able to S.A.t treating patients faster, increase daily patient throughput and provide a higher patient treatment safety.
EVENT: Advancing Patient Care Through Innovation: The Role of Proton Therapy.
IBA will be hosting a reception after the symposium on October 29, organized by University of Florida Proton Therapy Institute entitled: “Advancing Patient Care Through Innovation: The Role of Proton Therapy.”
The reception will S.A.t with an exclusive talk by Siddhartha Mukherjee, Pulitzer Prize Winner and Author of “The Emperor of All Maladies: A Biography of Cancer”.
*Proteus®ONE is the brand name of a new configuration of the Proteus®235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.
About IBA
IBA (Ion Beam Applications S.A.) iS.A.cancer diagnosticS.A.d treatment company and the worldwide technology leader in the field of proton therapy. The Company’s expertise lies in the development of next generation proton therapy technologieS.A.d radiopharmaceuticals that provide oncology care providers with premium quality serviceS.A.d equipment, including IBA’s leading fully integrated IntegraLab® radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.
Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has inS.A.led systemS.A.ross Europe and the US.A.d is expanding into emerging markets. The Company is focused on building suS.A.nable global growth for investors, providing solutions in the fight against cancer. IBA is listed on the pan-European stock exchange EURONEXT. (IBA:Reuters IBAB.BR and Bloomberg IBAB.BB).
Website: www.iba-protontherapy.com
Source: Ion Beam Applications
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!